Overexpression of PCBP2 contributes to poor prognosis and enhanced cell growth in human hepatocellular carcinoma
Author(s) -
Xiubing Zhang,
Hua Lu,
Daliang Yan,
Fengbo Zhao,
Jinxia Liu,
Huiling Zhou,
Jie Liu,
Miaomiao Wu,
Chengliang Zhang,
Yingying Chen,
Buyou Chen,
Baoying Hu
Publication year - 2016
Publication title -
oncology reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.094
H-Index - 96
eISSN - 1791-2431
pISSN - 1021-335X
DOI - 10.3892/or.2016.5167
Subject(s) - hepatocellular carcinoma , oncogene , cancer research , biology , cell cycle , sorafenib , apoptosis , cell culture , downregulation and upregulation , molecular medicine , cell growth , cell , gene , genetics
Poly(C)‑binding protein 2 (PCBP2) is a member of the PCBP family, and plays an important role in post‑transcriptional and translational regulation of various signaling molecules through direct binding to single‑stranded poly(C) motifs. PCBP2 has been reported to play a critical role in the development of multiple human tumors. However, whether PCBP2 participates in hepatocellular carcinoma (HCC) development remains largely elusive. Herein, we showed that PCBP2 was upregulated in human HCC tissues and cell lines. Overexpression of PCBP2 predicted significantly worsened prognosis in HCC patients, suggesting that PCBP2 may serve as a prognostic marker of HCC. In addition, we found that depletion of PCBP2 inhibited HCC cell proliferation, accompanying the increase in the cyclin‑dependent kinase inhibitor p27 level. Moreover, we found that high expression of PCBP2 may contribute to sorafenib resistance in HCC cells, involving dysregulated expression of Bax and Bcl‑2 proteins. In conclusion, our results suggest that PCBP2 may serve as a prognostic marker and potential therapeutic target of HCC.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom